Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer, Houston, TX 77030, USA.
GSK plc, Philadelphia, PA 19104, USA.
Future Oncol. 2024;20(30):2259-2270. doi: 10.1080/14796694.2024.2368450. Epub 2024 Jul 29.
To estimate projected US-based cost and time burden for patients with myelofibrosis and anemia treated with momelotinib compared with danazol. Cost and time burden were calculated based on the transfusion status of patients in the MOMENTUM trial and estimates extracted from previous studies. Reductions in transfusion associated with momelotinib are projected to result in cost and time savings compared with danazol in transfusion-dependent and transfusion-independent/requiring patients with myelofibrosis, respectively: annual medical costs ($53,143 and $46,455 per person), outpatient transfusion costs ($42,021 and $8,370 per person) and annual time savings (173 and 35 h per person). Fewer transfusions with momelotinib are projected to result in cost and time savings in patients with myelofibrosis and anemia compared with danazol.
评估与达那唑相比，米哚妥林治疗骨髓纤维化伴贫血的美国患者的预期成本和时间负担。成本和时间负担是根据 MOMENTUM 试验中患者的输血状况和从先前研究中提取的估计值计算得出的。与达那唑相比，米哚妥林可减少与输血相关的费用和时间，分别为：每年的医疗费用（每人 53143 美元和 46455 美元）、门诊输血费用（每人 42021 美元和 8370 美元）和每年节省的时间（每人 173 小时和 35 小时）。与达那唑相比，米哚妥林预计可减少骨髓纤维化伴贫血患者的输血次数，从而节省成本和时间。
